Menu
Search
|

Menu

Close
X

Checkpoint Therapeutics Inc CKPT.OQ (NASDAQ Stock Exchange Capital Market)

2.48 USD
-0.14 (-5.34%)
As of 4:00 PM EDT
chart
Previous Close 2.62
Open 2.64
Volume 65,619
3m Avg Volume 20,085
Today’s High 2.68
Today’s Low 2.44
52 Week High 10.50
52 Week Low 2.40
Shares Outstanding (mil) 32.02
Market Capitalization (mil) 89.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
3
FY15
1
EPS (USD)
FY18
-0.354
FY17
-1.001
FY16
-1.038
FY15
-1.399
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

No Data Available

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector:
Industry:
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1212.5544366

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

SPONSORED STORIES